HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysisM. Juliana McElrath, Danilo R. Casimiro, Zoe Moodie et al.|The Lancet|2008Cited by 699
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trialsT. Christopher Mast, John W. Shiver, Miguel Aste-Amézaga et al.|Vaccine|2009Cited by 276
Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy AdultsFrances Priddy, Jacob Lalezari, Randi Y. Leavitt et al.|Clinical Infectious Diseases|2008Cited by 246
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)Bart Corsaro, Meina Liang, Samuel Pine et al.|Bioanalysis|2021Cited by 60